Results 261 to 270 of about 6,763,423 (338)

Psychoactive substances: novel molecular insights and therapeutic potential for Alzheimer's disease. [PDF]

Transl Neurodegener
Fu C, Li X, Liu X, Zheng Y, Ma X, Zhang B, Chen S, Hu L, Su S, Wang X, Sun J, Yin Q, Wang Y, Fu X, Bao Y, Xue Y, Xin T, Lu L, Zou G.   +18 more
europepmc   +1 more source

High‐Efficacy Treatment in Neuromyelitis Optica Specturm Disorder Patients With Seropositive AQP4 Antibodies—A Real‐World Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To compare the effectiveness of high‐efficacy treatments (HET) and low‐efficacy treatments (LET) in NMOSD patients with anti‐aquaporin‐4 antibodies (AQP4‐ab). Methods In this multi‐center study, we analyzed 183 AQP4‐ab seropositive NMOSD patients who received immunosuppressive treatments (IST).
Xiang Li, Binbin Xue, Jia Li, Dewei Xie, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Xu Zhang, Junhui Xia, Jie Lin   +10 more
wiley   +1 more source

Pleiotropic Effects of the NSAID Fenamates on Chloride Channels: Opportunity for Ion Channelopathies? [PDF]

Pharmacol Res Perspect
Laghetti P, Saltarella I, Dell'Atti S, Desaphy JF, Altamura C.   +4 more
europepmc   +1 more source

Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The choice of the first disease modifying treatment (DMT) in multiple sclerosis (MS) is a topic of great interest, and whether high‐efficacy DMTs should be the first choice remains debated. We compared treatment outcomes (no evidence of disease activity [NEDA] and its components) between treatment‐naïve relapsing–remitting MS (RRMS ...
Sarmad Al‐Araji, Marcello Moccia, Alessia Bianchi, Charmaine Yam, Weaam Hamed, Suraya Mohamud, Alan J. Thompson, Frederik Barkhof, Ahmed T. Toosy, Olga Ciccarelli   +9 more
wiley   +1 more source

The Progress of Cognitive Dysfunction Impairment Caused by Temporal Lobe Epilepsy. [PDF]

J Mol Neurosci
Wang Q, Geng Y, Li X, Hao Y, Huang S.
europepmc   +1 more source

Early Intensive Versus Escalation Approach: Ten‐Year Impact on Disability in Relapsing Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the long‐term impact of early intensive treatment (EIT) versus escalation (ESC) strategies using high‐efficacy disease‐modifying therapies (HE‐DMTs) on disability progression in relapsing multiple sclerosis (RMS). Methods This observational study included 4878 RMS patients from the Italian Multiple Sclerosis Register ...
Pietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, Francesca Caputo, Marta Simone, Massimiliano Copetti, Damiano Paolicelli, Emilio Portaccio, Francesco Patti, Paola Perini, Vincenzo Brescia Morra, Alessia Di Sapio, Matilde Inglese, Carlo Pozzilli, Giacomo Lus, Giuseppe Salemi, Erica Curti, Giovanna De Luca, Paola Valentino, Eleonora Cocco, Paola Cavalla, Carlo Avolio, Alessandra Lugaresi, Antonio Gallo, Pietro Annovazzi, Maria A. Rocca, Clara Grazia Chisari, Massimo Filippi, Maria Pia Amato, Maria Trojano, on behalf of the Italian MS Register, Beatrice Biolzi, Daniele Dell’Anna, Daniele Di Giulio Cesare, Sonia Di Lemme, Chiara Di Tillio, Teresa Fonsdituri, Ilaria Maietta, Agata Marchese, Silvia Marinetto, Federica Martini, Cristiana Morano, Silvia Perugini, Giovanna Ramona Piredda, Chiara Raimondi, Ilaria Rossi, Valentina Tallarico, Stefania Treccarichi   +47 more
wiley   +1 more source

Moving the needle on immune checkpoint inhibitors with novel targets: are we being TIMid or LAGging behind? [PDF]

Oncologist
Park CL, Bedard PL.
europepmc   +1 more source

Discovery and Treatment of Action Potential‐Independent Myotonia in Hyperkalemic Periodic Paralysis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Hyperkalemic periodic paralysis (hyperKPP) is characterized by attacks of transient weakness. A subset of hyperKPP patients suffers from transient involuntary contraction of muscle (myotonia). The goal of this study was to determine mechanisms causing myotonia in hyperKPP.
Chris Dupont, Adam Deardorff, Murad Nawaz, Andrew A. Voss, Mark M. Rich   +4 more
wiley   +1 more source

Insomnia and Esketamine Add-On Therapy to Antidepressant Therapy in Patients with Treatment-Resistant Depression-A Pilot Study. [PDF]

Pharmaceuticals (Basel)
Szawarnoga D, Fojcik J, Górski M, Pałasz A, Krzystanek M.   +4 more
europepmc   +1 more source

Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia, Stephane Rodriguez, Emilie Dugast, Christine Lebrun‐Frenay, Eric Thouvenot, Jérôme de Sèze, Emmanuelle Le Page, Sandra Vukusic, Inès Doghri, Eric Berger, Olivier Casez, Pierre Labauge, Aurélie Ruet, Catarina Raposo, Fabienne Le Frère, Arnaud B. Nicot, Sandrine Wiertlewski, Pierre‐Antoine Gourraud, Laure Michel, Laureline Berthelot, David‐Axel Laplaud   +20 more
wiley   +1 more source